Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: Final analysis of a SICOG phase III study

Giuseppe Frasci, G. D'Aiuto, P. Comella, R. Thomas, G. Botti, M. Di Bonito, V. De Rosa, G. Iodice, M. R. Rubulotta, G. Comella

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: Final analysis of a SICOG phase III study'. Together they form a unique fingerprint.

Medicine & Life Sciences